[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589385":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":38,"locations":48,"responsibleParty":132,"collaborators":134,"id":137,"slug":25,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":138,"sex":144,"minAge":145,"maxAge":25,"enrollmentInfo":146,"targetDuration":25,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Apixaban Arm","ACTIVE_COMPARATOR","Study participants will be randomized to twice daily oral administration of apixaban 5mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years or older, body weight of 60 kg or lower, serum creatinine of 1.5 mg\u002FdL or higher",[13],"Drug: Apixaban",{"label":15,"type":10,"description":16,"interventionNames":17},"Rivaroxaban Arm","Study participants will be randomized to daily oral administration of rivaroxaban 20mg if creatinine clearance of 50 mL\u002Fmin or more. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL\u002Fmin.",[18],"Drug: Rivaroxaban",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Apixaban","Study participants will be randomized to twice daily oral administration of apixaban 5mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg\u002FdL.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Rivaroxaban","Study participants will be randomized to daily oral administration of rivaroxaban 20mg. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL\u002Fmin.",[15],[31,35],{"name":32,"affiliation":33,"role":34},"William E. Boden, MD","VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA","STUDY_CHAIR",{"name":36,"affiliation":37,"role":34},"Cara N Pellegrini","San Francisco VA Medical Center, San Francisco, CA",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},"Mustabeen Ashfaq, MS","CONTACT","(857) 364-6026","mustabeen.ashfaq@va.gov",{"name":45,"role":41,"phone":46,"phoneExt":25,"email":47},"Paul A Monach, MD PhD","(857) 364-5552","Paul.Monach@va.gov",[49,66,82,98,115],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Miami VA Healthcare System, Miami, FL","RECRUITING","Miami","Florida","33125","United States",{"type":57,"coordinates":58},"Point",[59,60],-80.19366,25.77427,{"lat":60,"lon":59},[63],{"name":64,"role":41,"phone":25,"phoneExt":25,"email":65},"Melyssa Sueiro","Melyssa.Sueiro@va.gov",{"facility":67,"status":51,"city":68,"state":69,"zip":70,"country":55,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Boston VA CSP Coordinating Center","Boston","Massachusetts","02111",{"type":57,"coordinates":72},[73,74],-71.05977,42.35843,{"lat":74,"lon":73},[77,79],{"name":78,"role":41,"phone":25,"phoneExt":25,"email":43},"Mustabeen Ashfaq",{"name":80,"role":41,"phone":25,"phoneExt":25,"email":81},"Jacqueline Dibella","Jacqueline.Dibella@va.gov",{"facility":33,"status":83,"city":68,"state":69,"zip":84,"country":55,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"NOT_YET_RECRUITING","02130-4817",{"type":57,"coordinates":86},[73,74],{"lat":74,"lon":73},[89,93,97],{"name":90,"role":41,"phone":91,"phoneExt":25,"email":92},"William E Boden, MD","857-364-5613","william.boden@va.gov",{"name":94,"role":41,"phone":95,"phoneExt":25,"email":96},"Britte Beaudette-Zlatanova, PhD","(857) 364-5762","Britte.Beaudette-Zlatanova@va.gov",{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"facility":99,"status":51,"city":100,"state":101,"zip":102,"country":55,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Minneapolis VA Call Center","Minneapolis","Minnesota","55417",{"type":57,"coordinates":104},[105,106],-93.26384,44.97997,{"lat":106,"lon":105},[109,112],{"name":110,"role":41,"phone":25,"phoneExt":25,"email":111},"Srihari I Raju","Srihari.Raju@va.gov",{"name":113,"role":41,"phone":25,"phoneExt":25,"email":114},"Olivia J Taylor","Olivia.Taylor@va.gov",{"facility":116,"status":51,"city":117,"state":118,"zip":119,"country":55,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"VA Portland Health Care System, Portland, OR","Portland","Oregon","97207-2964",{"type":57,"coordinates":121},[122,123],-122.67621,45.52345,{"lat":123,"lon":122},[126,129],{"name":127,"role":41,"phone":25,"phoneExt":25,"email":128},"Quinn Clarkson","Quinn.Clarkson@va.gov",{"name":130,"role":41,"phone":25,"phoneExt":25,"email":131},"Kevin A Osborn","Kevin.Osborn3@va.gov",{"type":133,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[135],{"name":136,"class":6},"Food and Drug Administration (FDA)","100589385",false,"NCT06953726","Comparing the Safety and Efficacy of Apixaban and Rivaroxaban","CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial","VALIANT-AF-T","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male or female Veteran, aged 22 years or older\n2. Diagnosis of atrial fibrillation (AF) or atrial flutter (AFL) and currently taking either apixaban or rivaroxaban.\n3. CHA2DS2-Vasc of 3 or more\n4. Ability to take oral medication and self-reported willingness to adhere to the prespecified apixaban or rivaroxaban regimen\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study; notably use of antiplatelet agents or prior OAC use will not be an exclusion criterion:\n\n1. Current use of oral or injectable anticoagulation, without ability to switch to the assigned study medication\n2. Another indication for anticoagulation, such as pulmonary embolism\n3. Contraindication to oral anticoagulation\n4. Known bleeding diathesis\n5. Documented current pregnancy or lactation in the EHR or self-reported current pregnancy or lactation\n6. Known allergic reactions or intolerance to apixaban or rivaroxaban\n7. Most recent estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL\u002Fminute\u002F1.73m2. An eGFR result must have been obtained within 18 months before randomization.\n8. Known mechanical heart valve\n9. Known moderate-severe mitral stenosis\n10. Known history of left atrial occlusion, excision, or ligation\n11. Current or planned use of systemic ritonavir, itraconazole, or ketoconazole (topical use of ketoconazole only is allowed)\n12. Cardiac or thoracic surgery in the past 3 months","ALL","65 Years",{"count":147,"type":148},10000,"ESTIMATED","INTERVENTIONAL",[151],"PHASE4","* The trial will compare two anticoagulants (\"blood thinners\") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure.\n* The trial only enrolls patients with a diagnosis of atrial fibrillation (\"A Fib\") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban.\n* The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs.\n* The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.",[154],"Atrial Fibrillation",[154,156,157,158],"Ischemic Stroke","Bleeding","Major bleeding","2026-06-18",{"date":161,"type":162},"2026-06-22","ACTUAL",{"date":164,"type":162},"2026-06-01",{"date":166,"type":148},"2033-10-03",{"name":5,"class":6},5]